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ABSTRACT
Objective: The aim of this study was to evaluate the diagnostic performance 
of a multiparametric gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid 
(Gd-EOB-DTPA)-enhanced MRI examination for the estimation of liver dysfunction 
classified by the Model for End-Stage Liver Disease (MELD) score.
Results: Liver dysfunction can be assessed by different methods. In a logistic 
regression analysis, T1- and T2-weighted images were affected by impaired liver 
function. In the assessment of liver dysfunction, the reduction rate in T1 mapping 
sequences showed a significant correlation in simple and multiple logistic regression.
Conclusion: Changes in Gd-EOB-DTPA-enhanced MRI between plain images and 
images obtained during the hepatobiliary phase allowed good prediction of liver 
dysfunction, especially when using T1 mapping sequences.
Materials and Methods: A total of 199 patients underwent contrast-enhanced 
MRI with a hepatocyte-specific contrast agent at 3T. In the multivariable analysis, 
the full range of available MRI sequences was used to estimate the liver dysfunction 
of patients with various MELD scores. 
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INTRODUCTION
The assessment of liver function is essential for 
determining the prognosis and clinical management 
of patients with chronic liver disease and for patients 
undergoing liver surgery [1, 2]. 
Several tests have been proposed or are used in daily 
clinical practice to assess liver function, ranging from tests 
based on laboratory values to metabolic tests. A widely 
used assessment is the Model for End-Stage Liver Disease 
(MELD) score. The MELD score combines several 
biochemical values (serum bilirubin, serum creatinine, 
and the international normalized ratio for prothrombin 
time) to determine liver function, serving as an indicator 
for patient treatment [3]. The most common metabolic 
test is the indocyanine green (ICG) clearance test, which 
uses an optical measurement technique to determine 
the blood clearance rate of intravenously injected ICG 
[4, 5]. New non-invasive technics are rising to analyze 
liver fibrosis, for example, Afdhal et al. showed that 
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FibroScan (vibration-controlled transient elastography) 
provides an accurate assessment of liver fibrosis in 
patients with hepatitis B or C in comparison to histology 
[6]. These tests are suitable for measurement of global 
liver function; however, heterogeneous liver function with 
areas of regional dysfunction or hepatic compensation of 
local defects can only be assessed non-invasively with 
imaging techniques.
Abdominal ultrasound is useful for image-based 
diagnosis of liver function. Ultrasound elastography (US-
RTE) can be used to measure liver stiffness, thus allowing 
an indirect assessment of liver function [7, 8]. However, 
the diagnostic value of US-RTE is restricted by limited 
reproducibility and the examiner-dependence of the 
method [9]. 
In addition to ultrasound imaging, MRI of 
the liver currently represents the gold standard of 
diagnostic methods. Several studies have demonstrated 
a correlation between hepatic gadolinium ethoxybenzyl-
diethylenetriaminepentaacetic acid (Gd-EOB-DTP) 
uptake and liver function. A common analysis is the 
measurement of the signal intensity (SI) of T1-weighted 
volumetric interpolated breathhold examination- (VIBE-) 
sequences. Regarding SI-based measurements after Gd-
EOB-DTPA administration, various SI ratios, such as the 
relative enhancement of the liver corrected by the spleen 
or muscle, have been used to assess liver function [10–15]. 
The evaluation of T1 relaxation time is an alternative 
approach to the direct measurement of SI and has recently 
gained attention [12, 16–19]. Haimerl et al. recently 
compared different SI and T1 relaxometry scores to detect 
the most relevant parameter derived from Gd-EOB-DTPA-
enhanced MRI for assessment of liver function [20]. 
Scores based on T1 relaxometry were superior to SI-based 
indices for the assessment of liver function. 
In addition to T1-weighted sequence analysis, some 
authors have reported the benefit of diffusion-weighted 
MRI in analyzing liver function [21–24]. The use of other 
MRI sequences such as T2-weighted images has not been 
analyzed.
The purpose of this study was to evaluate the 
diagnostic performance of multiparametric Gd-EOB-
DTPA-enhanced MRI for the estimation of liver classified 
by the MELD score. Instead of focusing on a single MRI 
sequence, we examined the full range of available MRI 
sequences to estimate liver function in a multivariable 
analysis. 
RESULTS
Patient characteristics stratified by the MELD score 
are summarized in Table 1. Patients were subdivided into 
two groups: normal liver function (NLF) and impaired 
liver function group (ILF). The mean MELD score was 
7.7 (± 1.3) for NLF and 14.9 (± 3.7) for the ILF.
The logistic regression analysis, with the MELD 
score as a dependent variable, (Table 2) showed that 6 of 
the 13 MR sequences including all relative scores were 
able to classify significantly (p < 0.05) liver dysfunction 
(Table 2). 
The MR scores and MR sequences with a significant 
association were included in a multiple logistic regression 
analysis. The result is shown in Table 3. In this analysis, 
only the reduction rate between the 3D T1 mapping 
sequence remained a significant influencing factor for the 
MELD score (Figure 1).
DISCUSSION
Our results showed that liver dysfunction can be 
assessed by different methods. The logistic regression 
analysis revealed, that the T1- and T2-weighted images 
were affected by impaired liver function.
Changes in liver function are often related to liver 
fibrosis. Liver fibrosis is characterized by destruction 
of the lobular and vascular architecture and nodular 
regeneration of liver tissue. Fibrosis of liver tissue 
results in extracellular accumulation of collagen fibers, 
proteoglycans, and other macromolecules [25]. Diffusion 
weighted imaging (DWI) measures the diffusion of water 
molecules in biological tissues and quantifies the water 
diffusion processes with the apparent diffusion coefficient 
(ADC) [26–28]. Theoretically, extracellular collagen 
fibers, glucosamine, and proteoglycans could inhibit 
the molecular diffusion of water, resulting in reduced 
diffusion [26, 28–30]. However, no significant correlation 
was found in the ADC analysis for this patient cohort.
Notably, the plain in-phase images of the T1-
weighted 3D VIBE sequence were able to classify liver 
dysfunction significantly, while the plain fat suppressed (fs) 
T1-weighted sequence showed no significant classification. 
This finding might be due to fat suppression, indicating an 
impact of fat tissue on liver function. This idea is supported 
by the fact that the T2-weighted half Fourier single shot 
turbo spinecho (HASTE) sequence (no fat suppression) 
also showed a significant result in classifying liver 
dysfunction. However, in the present study, this influence 
was not fully defined, and further studies are needed.
Many technical parameters, such as the 
radiofrequency amplifier, receiver coils, B1-field 
heterogeneity, repetition times (TR) and respiratory motion, 
influence absolute values of SI measurements [19, 31, 32]. 
To overcome this influence, the sequences must be 
corrected; we calculated the relative change in SI for plain 
and contrast-enhanced images to measure liver function 
using T1-weighted images after applying the contrast agent 
Gd-EOB-DTPA. The liver-specific contrast agent Gadoxetic 
acid (Gd-EOB-DTPA; Primovist®, Bayer Healthcare, 
Berlin) is an ionic complex consisting of gadolinium (III) 
and the ligand ethoxybenzyl-diethylenetriaminepentaacetic 
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Table 1: Patient characteristics
All (n = 199) NLF (n = 142) ILF (n = 57)
Age (years) 60.0 ± 12.9 59.8 ± 13.5 60.6 ± 11.3
Sex, n (%)
 Male 153 (77) 107 (75) 46 (81)
 Female 46 (23) 35 (25) 11 (19)
Weight (kg) 83.1 ± 16.2 84.9 ± 17.7 83.5 ± 12.1
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.8 ± 0.1
MELD score 
(range)
9.8 ± 4.0
(6–30)
7.7 8 ± 1.3
(6–10)
14.9 ± 3.7
(11–30)
Table 1 shows the patient characteristics for the subgroups.
Data presented as the means ± standard deviation.
NLF: Normal liver function.
ILF: Impaired liver function.
Table 2: Logistic regression
Independent variable NLF (n = 142) ILF (n = 57) OR (95%-CI) AUC p-value
T1 mapping 3D
 T1 plain [ms] 770.9 ± 130.1 758.1 ± 143.6 0.99 (0.97, 1.02)** 0.584 0.544
 T1 HBP [ms] 345.9 ± 93.6 460.5 ± 129.2 1.09 (1.06, 1.13)** 0.751 ≤0.001
 RR (plain and HBP) 0.5 ± 0.1 0.4 ± 0.1 0.31 (0.22, 0.44)* 0.825 ≤0.001
T1 3D VIBE
 In-phase plain [a.u.] 215.5 ± 70.7 218.7 ± 42.8 0.88 (0.81, 0.96)** 0.605 0.005
 Opposed-phase plain [a.u.] 237.4 ± 37.6 222.1 ± 37.9 1.02 (0.97, 1.06)** 0.574 0.517
 fs plain [a.u.] 187.6 ± 32.9 187.5 ± 30.6 1.00 (0.91, 1.10)** 0.513 0.987
 fs HBP [a.u.] 357.8 ± 82.6 283.1 ± 60.5 0.86 (0.81, 0.91)** 0.772 ≤0.001
 RE (fs plain and HBP) 0.9 ± 0.3 0.5 ± 0.3 0.67 (0.59, 0.77)* 0.820 ≤0.001
T2 HASTE 271.3 ± 70.8 240.1 ± 68.2 0.94 (0.89, 0.98)** 0.622 0.006
T2 BLADE fs 160.9 ± 55.5 168.3 ± 52.1 1.02 (0.97, 1.08)** 0.547 0.390
ADC (mm2/s) 1.164 × 10
−3 ± 
0.297 × 10−3
1.215 × 10−3 ± 
0.209 × 10−3 1.07 (0.96, 1.21) 0.545 0.232
Table 2 shows the results of the logistic regression analyses with the MELD score as a dependent variable.
NLF: Normal liver function; ILF: Impaired liver function.
OR: Odds ratio; CI: Confidence interval; AUC: Area under the curve, p: Level of significance.
*per 0.1, **per 10 units.
Table 3: Multiple logistic regression
Independent variable OR (95%-CI) p-value
T1 mapping 3D HBP 1.03 (0.98, 1.08)** 0.307
RR T1 mapping 3D (plain and HBP) 0.41 (0.21, 0.82)* 0.012
T1 3D VIBE in plain 0.92 (0.80, 1.05)** 0.219
T1 3D VIBE fs HBP 1.03 (0.93, 1.15)** 0.555
RE T1 3D VIBE (fs plain and HBP) 0.92 (0.73, 1.15)* 0.446
T2 HASTE 0.96 (0.90, 1.02)** 0.214
Table 3 shows the results of the multiple logistic regression analysis with the MELD score as a dependent variable.
OR: Odds ratio; CI: Confidence interval; p: Level of significance.
*per 0.1, **per 10 units.
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acid (EOB-DTPA). Gadolinium shortens the spin-lattice 
relaxation (T1) time in the corresponding tissue, leading to 
an increase in SI on T1-weighted images [33–36].
The biochemical properties allow a characteristic 
late phase (HBP) [33–35, 37]. The ethoxybenzyl group 
promotes the transport of Gd-EOB-DTPA into hepatocytes 
through organ-anion transporters (OATPB1/B3) located in 
the sinusoids [38–41], while Gd-EOB-DTPA is excreted 
at the canalicular membrane by ATP-dependent multidrug 
resistance protein 2 (MRP2) [42, 43]. Excretion of Gd-
EOB-DTPA into the biliary ducts is limited, which 
causes a temporary enhancement in liver cells [44]. In 
patients with normal liver parenchyma, the hepatocyte-
specific contrast agent shows specific enhancement in 
the liver parenchyma [37–40]. Since the accumulation of 
Gd-EOB-DTPA depends on the number of functioning 
hepatocytes, in the case of liver fibrosis and cirrhosis, 
the enhancement is reduced, and changes in the liver 
parenchyma are reflected by Gd-EOB-DTPA uptake [15, 
45–48]. While the plain fs T1-weighted images showed 
no significant value for classifying liver dysfunction, 
the contrast enhancement in the HBP images showed a 
significant result. This correlation was even stronger when 
calculating the relative change in SI. However, neither 
the fs T1-weighted images during the HBP nor the RE 
remained significant influencing factors in the multiple 
logistic regression.
In the plain T1 maps, no significant correlation with 
liver dysfunction, classified by the MELD score, could be 
observed. 
Controversy currently exists regarding the 
extent to which the plain T1 relaxation time of the 
liver is influenced by changes in the liver parenchyma. 
The T1 relaxation time can be prolonged in plain images in 
cases of tissue remodeling in liver fibrosis, characterized 
by inflammation and consequent edema [19, 49, 50]. In 
contrast, in the advanced stages of liver fibrosis, decreased 
T1 relaxation times have been reported [51]. This reduction 
in T1 relaxation time might be due to increased deposition 
of paramagnetic macromolecules such as collagen tissue 
that have a lower water content [52, 53]. 
In simple and multiple logistic regression, we 
showed that liver dysfunction can be predicted, using the 
reduction rate in the T1 sequences. Regarding the question 
of whether SI-based-scores or T1 relaxation time scores 
should be used, we agree with Haimerl et al. [20] - a more 
reliable outcome can be found using T1 mapping. 
In conclusion, Gd-EOB-DTPA-enhanced MRI 
allowed good prediction of liver dysfunction. It may 
serve as an appropriate image-based tool for staging liver 
function before liver surgery, detecting silent disease, or 
revealing existing disease.
MATERIALS AND METHODS
Patient inclusion
The institutional review board approved this 
retrospective study. Between 03/2016 and 12/2016, 215 
Gd-EOB-DTPA-enhanced MRI examinations of the liver 
were performed. Sixteen patients were excluded from the 
study due to inability to complete the full MRI protocol 
or the presence of severe motion artifacts as a result of 
poor breath-holding technique. Finally, 199 patients 
were included in this study; the corresponding patient 
characteristics are listed in Table 1. 
Figure 1: Scatterplot of the reduction rate between plain and contrast enhanced of T1 mapping sequences in correlation 
to the MELD score. The solid line indicates the cut off between normal (NLF) and impaired liver function (ILF).
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Evaluation of liver function (using established 
clinical methods)
We used an established clinical scoring system, the 
MELD score, to assess total liver function. The MELD 
score is calculated using biochemical blood parameters as 
follows:
1 10 0 957 0 378( ) = ( ) +MELD * * serumcreatinine * total bilirub( . ln . ln in
  * prothrombin time INR
( ) +
( ) +
1 12
0 643
.
ln , .
To avoid negative scores, any value less than 1 was 
given a value of 1 (e.g., if the serum bilirubin value was 
0.6, a value of 1.0 was used).
Subsequently, the patients were divided into two 
groups according to their liver function as determined 
by the MELD score. Following the approach described 
previously by Verloh et al., a MELD score below ten 
was considered indicative of normal liver function, and a 
MELD score above 10 indicated impaired liver function 
[12]. Patients with impaired liver function (n = 57) had 
different diagnostic assumptions: 26 patients with ethyl-
induced liver damage, 17 patients with chronic viral 
infection, five patients with a non-alcoholic fatty liver 
disease, three patients with autoimmune disease, six 
patients with other diseases associated with an impaired 
liver function such as sclerosing cholangitis.
MRI
All imaging was performed using a clinical whole 
body 3T system (MAGNETOM Skyra, Siemens Healthcare). 
A combination of body and spine array coil elements 
(18-channel body matrix coil, 24-channel spine matrix coil) 
was used for signal reception. Images were acquired using 
various sequences before (native) and 20 min after contrast 
agent administration (hepatobiliary phase, HBP). All MR 
sequences with their respective parameters are shown in the 
Supplementary Materials (Supplementary Table 1).
Gd-EOB-DTPA (Primovist; Bayer Schering Pharma 
AG, Berlin, Germany) was used as the liver-specific 
contrast agent and was administered via bolus injection 
(0.1 ml/kg body weight) with a flow rate of 1 ml/s and was 
subsequently flushed with 20 ml NaCl.
Image analysis
The mean SI values on T1-weighted images and the 
T1 relaxation times on T1 maps of the liver were measured 
using operator-defined regions of interest (ROIs).
Four circular ROIs were manually positioned by 
an experienced radiologist in the liver parenchyma at 
identical locations in all sequences (see the Supplementary 
Materials for details) at the level of the portal fork, three in 
right liver lobe, one in the left liver lobe. Visible vessels, 
liver lesions or imaging artifacts were excluded. The 
sizes of the ROIs ranged from 1.0 to 2.5 cm2, attempting 
to primarily take the largest diameter. Focal liver 
parenchyma damage was not found in any of the patients. 
ROIs were manually adjusted between sequences before 
and after Gd-EOB-DTPA administration in the case of 
patient movement. The mean values of these ROIs were 
then calculated and were considered representative for the 
entire liver. 
Relative changes between the plain and contrast-
enhanced series during the HBP were calculated as 
follows: 
(2) Relative enhancement of SI (RE) = 
SI SI
SI
HBP plain
plain
−
(3) Reduction rate of the T1 relaxation time (RR) = T T
T
plain HBP
plain
1 1
1
−  
Statistical analysis
The statistical analysis was performed using 
IBM SPSS Statistics (Version 24, Chicago, IL) and 
R 3.2.1. All data are presented as means ± standard 
deviation if not specified otherwise. Logistic regression 
analyses of MRI sequences were used to determine their 
assessment of liver function as classified according to 
the MELD score. Then, multiple logistic regression of 
all significant values (inclusion criterion: p ≤ 0.05) was 
performed. The statistical significance level was set to 
0.05 (two-sided).
Abbreviations
MELD-Score: Model for End-Stage Liver Disease 
Score; ICG: Indocyanine green; US-RTE: Ultrasound 
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intensity; ROI: Region-of-interest; RE: Relative 
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